The DOI matches its OpenAlex record; 26 of the 26 references it cites were found in a registry or an index.
Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007–08 Season
Open accessAbstract
In Europe, the 2007-08 winter season was dominated by influenza virus A (H1N1) circulation through week 7, followed by influenza B virus from week 8 onward. Oseltamivir-resistant influenza viruses A (H1N1) (ORVs) with H275Y mutation in the neuraminidase emerged independently of drug use. By country, the proportion of ORVs ranged from 0% to 68%, with the highest proportion in Norway. The average weighted prevalence of ORVs across Europe increased gradually over time, from near 0 in week 40 of 2007 to 56% in week 19 of 2008 (mean 20%). Neuraminidase genes of ORVs possessing the H275Y substitution formed a homogeneous subgroup closely related to, but distinguishable from, those of oseltamivir-sensitive influenza viruses A (H1N1). Minor variants of ORVs emerged independently, indicating multiclonal ORVs. Overall, the clinical effect of ORVs in Europe, measured by influenza-like illness or acute respiratory infection, was unremarkable and consistent with normal seasonal activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Data Analysis Using Regression and Multilevel/Hierarchical Models
Gelman, A., & Hill, J. (2006) · doi:10.1017/cbo9780511790942 · Cited by 13,597
Models for Discrete Longitudinal Data
(2005) · Springer Series in Statistics · doi:10.1007/0-387-28980-1 · Cited by 1,021
Potier, M., Mameli, L., Bélisle, M., Dallaire, L., & Melançon, S. B. (1979) · Analytical Biochemistry · doi:10.1016/0003-2697(79)90362-2 · Cited by 815
Resistant influenza A viruses in children treated with oseltamivir: descriptive study
Kiso, M., Mitamura, K., Sakai-Tagawa, Y., Shiraishi, K., Kawakami, C., Kimura, K., Hayden, F. G., Sugaya, N., & Kawaoka, Y. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16934-1 · Cited by 786
The war against influenza: discovery and development of sialidase inhibitors
von Itzstein, M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2400 · Cited by 702
Sheu, T. G., Deyde, V. M., Okomo-Adhiambo, M., Garten, R. J., Xu, X., Bright, R. A., Butler, E. N., Wallis, T. R., Klimov, A. I., & Gubareva, L. V. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00555-08 · Cited by 480
Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic
Ward, P., Small, I., Smith, J., Suter, P., & Dutkowski, R. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki018 · Cited by 428
The global impact of influenza on morbidity and mortality
Simonsen, L. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00099-7 · Cited by 399
Ives, J. A. L., Carr, J. A., Mendel, D. B., Tai, C. Y., Lambkin, R., Kelly, L., Oxford, J. S., Hayden, F. G., & Roberts, N. A. (2002) · Antiviral Research · doi:10.1016/s0166-3542(02)00053-0 · Cited by 379
Monto, A. S., McKimm-Breschkin, J. L., Macken, C., Hampson, A. W., Hay, A., Klimov, A., Tashiro, M., Webster, R. G., Aymard, M., Hayden, F. G., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01339-05 · Cited by 364
Self-citation
Cited by
Krammer, F., Smith, G. J. D., Fouchier, R. A. M., Peiris, M., Kedzierska, K., Doherty, P. C., Palese, P., Shaw, M. L., Treanor, J., Webster, R. G., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0002-y · Cited by 1,570
Influenza Hemagglutinin and Neuraminidase Membrane Glycoproteins
Gamblin, S. J., & Skehel, J. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r110.129809 · Cited by 638
Grohskopf, L. A., Sokolow, L. Z., Broder, K. R., Olsen, S. J., Karron, R. A., Jernigan, D. B., & Bresee, J. S. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6505a1 · Cited by 593
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
Shiraki, K., & Daikoku, T. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107512 · Cited by 573
Influenza Virus Neuraminidase Structure and Functions
McAuley, J. L., Gilbertson, B. P., Trifkovic, S., Brown, L. E., & McKimm-Breschkin, J. L. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00039 · Cited by 466
Drug resistance in influenza A virus: the epidemiology and management
Hussain, M., Galvin, H., Haw, T. Y., Nutsford, A., & Husain, M. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s105473 · Cited by 439
Continuing challenges in influenza
Webster, R. G., & Govorkova, E. A. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12462 · Cited by 399
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
McKimm‐Breschkin, J. L. (2013) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12047 · Cited by 390
Influenza virus resistance to neuraminidase inhibitors
Samson, M., Pizzorno, A., Abed, Y., & Boivin, G. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.03.014 · Cited by 343
Hurt, A. C., Besselaar, T. G., Daniels, R. S., Ermetal, B., Fry, A., Gubareva, L., Huang, W., Lackenby, A., Lee, R. T. C., Lo, J., et al. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.06.001 · Cited by 270
Self-citationTramontana, A. R., George, B., Hurt, A. C., Doyle, J. S., Langan, K., Reid, A. B., Harper, J. M., Thursky, K., Worth, L. J., Dwyer, D. E., et al. (2010) · Emerging Infectious Diseases · doi:10.3201/eid1607.091691 · Cited by 127
Metadata
- Authors
- Meijer, A., Lackenby, A., Hungnes, O., Lina, B., van der Werf, S., Schweiger, B., Opp, M., Paget, J., van de Kassteele, J., Hay, A. J., Zambon, M. C. F. A., & Scheme, O. B. O. T. E. I. S.
- Venue
- Emerging infectious diseases
- Publisher
- Centers for Disease Control and Prevention
- Published
- 2009-03-31
- Volume
- 15
- Issue
- 4
- Pages
- 552-560
- ISSN
- 1080-6040 (ISSN-L)
- OpenAlex
- W2135934555
- Cited by
- 362
- References
- 26
- FWCI
- 40.92
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.